UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE
- Type
- Non-covered entity
- Where
- KANSAS CITY, KS
- Received
- $612,210 in 161 records, 2019 to 2025 ($0 general, $612,210 research)
- Source
- CMS Open Payments search ↗
On this site
- Plan sponsor: UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE, INC. Fuzzy (name and state)
- Federal award recipient: UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE, INC. Fuzzy (name and state)
- Nonprofit: UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE Fuzzy (name and state)
- Patent assignee: University of Kansas Medical Center Research Institute, Inc. Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | Research payment | 9 | $24,852 |
| 2024 | Research payment | 44 | $143,890 |
| 2023 | Research payment | 58 | $286,734 |
| 2021 | Research payment | 25 | $83,611 |
| 2020 | Research payment | 20 | $56,160 |
| 2019 | Research payment | 5 | $16,961 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Janssen Research & Development, LLC | 133 | $570,308 | 2019–2025 |
| Medical Device Business Services, Inc. | 28 | $41,901 | 2020–2023 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 161 | $612,210 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-09-29 | Janssen Research & Development, LLC | $600 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2025 |
| 2025-09-15 | Janssen Research & Development, LLC | $10,413 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2025 |
| 2025-09-04 | Janssen Research & Development, LLC | $133 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2025 |
| 2025-08-28 | Janssen Research & Development, LLC | $166 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2025 |
| 2025-08-08 | Janssen Research & Development, LLC | $1,890 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2025 |
| 2025-07-28 | Janssen Research & Development, LLC | $1,000 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2025 |
| 2025-05-22 | Janssen Research & Development, LLC | $8,480 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2025 |
| 2025-04-14 | Janssen Research & Development, LLC | $2,004 | Research payment | Cash or cash equivalent | A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Receiv | 2025 | |
| 2025-03-31 | Janssen Research & Development, LLC | $166 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2025 |
| 2024-12-13 | Janssen Research & Development, LLC | $2,417 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu | 2024 | |
| 2024-11-28 | Janssen Research & Development, LLC | $166 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2024 |
| 2024-11-25 | Janssen Research & Development, LLC | $13,401 | Research payment | Cash or cash equivalent | A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Co | 2024 | |
| 2024-11-25 | Janssen Research & Development, LLC | $9,490 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2024 |
| 2024-10-25 | Janssen Research & Development, LLC | $6,595 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2024 |
| 2024-10-23 | Janssen Research & Development, LLC | $1,075 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu | 2024 | |
| 2024-10-17 | Janssen Research & Development, LLC | $8,464 | Research payment | Cash or cash equivalent | SPRAVATO Drug, Neuroscience | A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression | 2024 |
| 2024-09-23 | Janssen Research & Development, LLC | $1,890 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Safety and Efficacy Study of JNJ-68284528 (ciltacabtagene autoleucel) Out-of-Specification (OOS) for Commercial Releas | 2024 |
| 2024-09-19 | Janssen Research & Development, LLC | $1,075 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu | 2024 | |
| 2024-09-09 | Janssen Research & Development, LLC | $8,559 | Research payment | Cash or cash equivalent | A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Receiv | 2024 | |
| 2024-09-09 | Janssen Research & Development, LLC | $1,000 | Research payment | Cash or cash equivalent | A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Receiv | 2024 | |
| 2024-09-05 | Janssen Research & Development, LLC | $575 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2024 |
| 2024-09-02 | Janssen Research & Development, LLC | $35,809 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2024 |
| 2024-09-02 | Janssen Research & Development, LLC | $2,415 | Research payment | Cash or cash equivalent | A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Receiv | 2024 | |
| 2024-08-19 | Janssen Research & Development, LLC | $1,000 | Research payment | Cash or cash equivalent | A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Receiv | 2024 | |
| 2024-08-16 | Janssen Research & Development, LLC | $1,500 | Research payment | Cash or cash equivalent | A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Receiv | 2024 | |
| 2024-08-15 | Janssen Research & Development, LLC | $1,415 | Research payment | Cash or cash equivalent | TREMFYA Drug, Immunology | A Phase 2 Multi Center Randomized Placebo controlled Double blind Proof of Concept Study to Evaluate Guselkumab for the | 2024 |
| 2024-08-05 | Janssen Research & Development, LLC | $500 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2024 |
| 2024-07-29 | Janssen Research & Development, LLC | $166 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2024 |
| 2024-07-08 | Janssen Research & Development, LLC | $1,000 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2024 |
| 2024-06-07 | Janssen Research & Development, LLC | $500 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Safety and Efficacy Study of JNJ-68284528 (ciltacabtagene autoleucel) Out-of-Specification (OOS) for Commercial Releas | 2024 |
| 2024-06-07 | Janssen Research & Development, LLC | $166 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2024 |
| 2024-06-03 | Janssen Research & Development, LLC | $1,000 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2024 |
| 2024-05-24 | Janssen Research & Development, LLC | $63 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu | 2024 | |
| 2024-05-20 | Janssen Research & Development, LLC | $3,082 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Safety and Efficacy Study of JNJ-68284528 (ciltacabtagene autoleucel) Out-of-Specification (OOS) for Commercial Releas | 2024 |
| 2024-05-16 | Janssen Research & Development, LLC | $1,000 | Research payment | Cash or cash equivalent | A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Receiv | 2024 | |
| 2024-05-13 | Janssen Research & Development, LLC | $2,216 | Research payment | Cash or cash equivalent | A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Receiv | 2024 | |
| 2024-05-06 | Janssen Research & Development, LLC | $1,948 | Research payment | Cash or cash equivalent | SPRAVATO Drug, Neuroscience | A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression | 2024 |
| 2024-05-03 | Janssen Research & Development, LLC | $1,976 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Safety and Efficacy Study of JNJ-68284528 (ciltacabtagene autoleucel) Out-of-Specification (OOS) for Commercial Releas | 2024 |
| 2024-04-29 | Janssen Research & Development, LLC | $133 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2024 |
| 2024-04-22 | Janssen Research & Development, LLC | $1,000 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Safety and Efficacy Study of JNJ-68284528 (ciltacabtagene autoleucel) Out-of-Specification (OOS) for Commercial Releas | 2024 |
| 2024-04-22 | Janssen Research & Development, LLC | $650 | Research payment | Cash or cash equivalent | SPRAVATO Drug, Neuroscience | A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression | 2024 |
| 2024-04-11 | Janssen Research & Development, LLC | $290 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Safety and Efficacy Study of JNJ-68284528 (ciltacabtagene autoleucel) Out-of-Specification (OOS) for Commercial Releas | 2024 |
| 2024-04-08 | Janssen Research & Development, LLC | $2,334 | Research payment | Cash or cash equivalent | A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Receiv | 2024 | |
| 2024-04-08 | Janssen Research & Development, LLC | $1,117 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Safety and Efficacy Study of JNJ-68284528 (ciltacabtagene autoleucel) Out-of-Specification (OOS) for Commercial Releas | 2024 |
| 2024-04-04 | Janssen Research & Development, LLC | $5,821 | Research payment | Cash or cash equivalent | A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Receiv | 2024 | |
| 2024-04-04 | Janssen Research & Development, LLC | $1,000 | Research payment | Cash or cash equivalent | A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Receiv | 2024 | |
| 2024-03-25 | Janssen Research & Development, LLC | $1,000 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Safety and Efficacy Study of JNJ-68284528 (ciltacabtagene autoleucel) Out-of-Specification (OOS) for Commercial Releas | 2024 |
| 2024-03-18 | Janssen Research & Development, LLC | $2,415 | Research payment | Cash or cash equivalent | A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Co | 2024 | |
| 2024-03-15 | Janssen Research & Development, LLC | $575 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Safety and Efficacy Study of JNJ-68284528 (ciltacabtagene autoleucel) Out-of-Specification (OOS) for Commercial Releas | 2024 |
| 2024-03-14 | Janssen Research & Development, LLC | $7,285 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Safety and Efficacy Study of JNJ-68284528 (ciltacabtagene autoleucel) Out-of-Specification (OOS) for Commercial Releas | 2024 |
| 2024-02-16 | Janssen Research & Development, LLC | $1,000 | Research payment | Cash or cash equivalent | A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Co | 2024 | |
| 2024-02-15 | Janssen Research & Development, LLC | $6,295 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Safety and Efficacy Study of JNJ-68284528 (ciltacabtagene autoleucel) Out-of-Specification (OOS) for Commercial Releas | 2024 |
| 2024-02-12 | Janssen Research & Development, LLC | $2,508 | Research payment | Cash or cash equivalent | A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Receiv | 2024 | |
| 2023-12-25 | Janssen Research & Development, LLC | $166 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2023 |
| 2023-12-18 | Janssen Research & Development, LLC | $29,204 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu | 2023 | |
| 2023-12-14 | Janssen Research & Development, LLC | $2,212 | Research payment | Cash or cash equivalent | A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Co | 2023 | |
| 2023-12-14 | Janssen Research & Development, LLC | $294 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Safety and Efficacy Study of JNJ-68284528 (ciltacabtagene autoleucel) Out-of-Specification (OOS) for Commercial Releas | 2023 |
| 2023-12-11 | Janssen Research & Development, LLC | $575 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2023 |
| 2023-12-08 | Janssen Research & Development, LLC | $1,575 | Research payment | Cash or cash equivalent | A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Co | 2023 | |
| 2023-11-30 | Janssen Research & Development, LLC | $6,295 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2023 |
| 2023-11-27 | Janssen Research & Development, LLC | $5,821 | Research payment | Cash or cash equivalent | A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Receiv | 2023 | |
| 2023-11-27 | Janssen Research & Development, LLC | $1,500 | Research payment | Cash or cash equivalent | A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Receiv | 2023 | |
| 2023-11-27 | Janssen Research & Development, LLC | $1,000 | Research payment | Cash or cash equivalent | A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Receiv | 2023 | |
| 2023-11-27 | Janssen Research & Development, LLC | $1,000 | Research payment | Cash or cash equivalent | A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Receiv | 2023 | |
| 2023-11-16 | Janssen Research & Development, LLC | $3,000 | Research payment | Cash or cash equivalent | TREMFYA Drug, Immunology | A Phase 2 Multi Center Randomized Placebo controlled Double blind Proof of Concept Study to Evaluate Guselkumab for the | 2023 |
| 2023-11-10 | Janssen Research & Development, LLC | $1,575 | Research payment | Cash or cash equivalent | A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Co | 2023 | |
| 2023-11-06 | Janssen Research & Development, LLC | $3,166 | Research payment | Cash or cash equivalent | Macitentan in inoperable or persistent recurrent chronic thromboembolic pulmonary hypertension A prospective randomized | 2023 | |
| 2023-11-06 | Janssen Research & Development, LLC | $2,900 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2023 |
| 2023-10-30 | Janssen Research & Development, LLC | $1,200 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2023 |
| 2023-10-27 | Janssen Research & Development, LLC | $2,508 | Research payment | Cash or cash equivalent | A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Receiv | 2023 | |
| 2023-10-16 | Janssen Research & Development, LLC | $783 | Research payment | Cash or cash equivalent | TREMFYA Drug, Immunology | A Phase 2 Multi Center Randomized Placebo controlled Double blind Proof of Concept Study to Evaluate Guselkumab for the | 2023 |
| 2023-10-09 | Janssen Research & Development, LLC | $1,200 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2023 |
| 2023-10-02 | Janssen Research & Development, LLC | $2,874 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Safety and Efficacy Study of JNJ-68284528 (ciltacabtagene autoleucel) Out-of-Specification (OOS) for Commercial Releas | 2023 |
| 2023-09-21 | Janssen Research & Development, LLC | $1,000 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2023 |
| 2023-09-07 | Janssen Research & Development, LLC | $93 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2023 |
| 2023-08-22 | Janssen Research & Development, LLC | $1,000 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Safety and Efficacy Study of JNJ-68284528 (ciltacabtagene autoleucel) Out-of-Specification (OOS) for Commercial Releas | 2023 |
| 2023-08-21 | Janssen Research & Development, LLC | $2,872 | Research payment | Cash or cash equivalent | A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Receiv | 2023 | |
| 2023-08-14 | Janssen Research & Development, LLC | $1,000 | Research payment | Cash or cash equivalent | A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Receiv | 2023 | |
| 2023-08-03 | Janssen Research & Development, LLC | $1,500 | Research payment | Cash or cash equivalent | A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Receiv | 2023 | |
| 2023-07-31 | Janssen Research & Development, LLC | $133 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2023 |
| 2023-07-28 | Janssen Research & Development, LLC | $1,300 | Research payment | Cash or cash equivalent | SPRAVATO Drug, Neuroscience | A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression | 2023 |
| 2023-07-17 | Janssen Research & Development, LLC | $2,375 | Research payment | Cash or cash equivalent | A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Receiv | 2023 | |
| 2023-07-06 | Janssen Research & Development, LLC | $650 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2023 |
| 2023-07-03 | Janssen Research & Development, LLC | $27,025 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Safety and Efficacy Study of JNJ-68284528 (ciltacabtagene autoleucel) Out-of-Specification (OOS) for Commercial Releas | 2023 |
| 2023-06-26 | Janssen Research & Development, LLC | $1,000 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2023 |
| 2023-06-19 | Janssen Research & Development, LLC | $1,300 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Safety and Efficacy Study of JNJ-68284528 (ciltacabtagene autoleucel) Out-of-Specification (OOS) for Commercial Releas | 2023 |
| 2023-06-12 | Janssen Research & Development, LLC | $5,684 | Research payment | Cash or cash equivalent | A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Receiv | 2023 | |
| 2023-06-12 | Janssen Research & Development, LLC | $2,500 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2023 |
| 2023-06-12 | Janssen Research & Development, LLC | $1,200 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2023 |
| 2023-06-12 | Janssen Research & Development, LLC | $575 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2023 |
| 2023-06-12 | Janssen Research & Development, LLC | $328 | Research payment | Cash or cash equivalent | SPRAVATO Drug, Neuroscience | A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression | 2023 |
| 2023-06-05 | Janssen Research & Development, LLC | $18,896 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Safety and Efficacy Study of JNJ-68284528 (ciltacabtagene autoleucel) Out-of-Specification (OOS) for Commercial Releas | 2023 |
| 2023-05-29 | Janssen Research & Development, LLC | $2,734 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2023 |
| 2023-05-25 | Janssen Research & Development, LLC | $31,132 | Research payment | Cash or cash equivalent | A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Co | 2023 | |
| 2023-05-15 | Janssen Research & Development, LLC | $6,621 | Research payment | Cash or cash equivalent | A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Receiv | 2023 | |
| 2023-05-08 | Janssen Research & Development, LLC | $15,030 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Safety and Efficacy Study of JNJ-68284528 (ciltacabtagene autoleucel) Out-of-Specification (OOS) for Commercial Releas | 2023 |
| 2023-05-05 | Janssen Research & Development, LLC | $5,821 | Research payment | Cash or cash equivalent | A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Receiv | 2023 | |
| 2023-05-05 | Janssen Research & Development, LLC | $1,500 | Research payment | Cash or cash equivalent | A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Receiv | 2023 | |
| 2023-04-10 | Janssen Research & Development, LLC | $13,903 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Safety and Efficacy Study of JNJ-68284528 (ciltacabtagene autoleucel) Out-of-Specification (OOS) for Commercial Releas | 2023 |
| 2023-03-13 | Janssen Research & Development, LLC | $3,319 | Research payment | Cash or cash equivalent | A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Receiv | 2023 | |
| 2023-03-09 | Janssen Research & Development, LLC | $7,280 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2023 |
| 2023-03-09 | Janssen Research & Development, LLC | $3,824 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2023 |
| 2023-03-06 | Janssen Research & Development, LLC | $1,000 | Research payment | Cash or cash equivalent | A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Receiv | 2023 | |
| 2023-03-06 | Janssen Research & Development, LLC | $234 | Research payment | Cash or cash equivalent | SPRAVATO Drug, Neuroscience | A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression | 2023 |
| 2023-03-03 | Janssen Research & Development, LLC | $2,902 | Research payment | Cash or cash equivalent | A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Receiv | 2023 | |
| 2023-02-28 | Janssen Research & Development, LLC | $9,370 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Safety and Efficacy Study of JNJ-68284528 (ciltacabtagene autoleucel) Out-of-Specification (OOS) for Commercial Releas | 2023 |
| 2023-02-17 | Janssen Research & Development, LLC | $15,206 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2023 |
| 2023-02-13 | Janssen Research & Development, LLC | $5,995 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Safety and Efficacy Study of JNJ-68284528 (ciltacabtagene autoleucel) Out-of-Specification (OOS) for Commercial Releas | 2023 |
| 2023-02-10 | Janssen Research & Development, LLC | $395 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2023 |
| 2023-01-30 | Janssen Research & Development, LLC | $20,885 | Research payment | Cash or cash equivalent | Macitentan in inoperable or persistent recurrent chronic thromboembolic pulmonary hypertension A prospective randomized | 2023 | |
| 2023-01-16 | Medical Device Business Services, Inc. | $300 | Research payment | Cash or cash equivalent | Safety and Effectiveness Evaluation of the Multi Electrode Radiofrequency Balloon Catheter for the Treatment of Symptoma | 2023 | |
| 2021-12-31 | Janssen Research & Development, LLC | $5,495 | Research payment | Cash or cash equivalent | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2021 | |
| 2021-12-13 | Medical Device Business Services, Inc. | $119 | Research payment | Cash or cash equivalent | Safety and Effectiveness Evaluation of the Multi Electrode Radiofrequency Balloon Catheter for the Treatment of Symptoma | 2021 | |
| 2021-12-03 | Medical Device Business Services, Inc. | $798 | Research payment | Cash or cash equivalent | Safety and Effectiveness Evaluation of the Multi Electrode Radiofrequency Balloon Catheter for the Treatment of Symptoma | 2021 | |
| 2021-11-11 | Janssen Research & Development, LLC | $2,750 | Research payment | Cash or cash equivalent | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2021 | |
| 2021-11-01 | Medical Device Business Services, Inc. | $1,335 | Research payment | Cash or cash equivalent | Safety and Effectiveness Evaluation of the Multi Electrode Radiofrequency Balloon Catheter for the Treatment of Symptoma | 2021 | |
| 2021-10-14 | Janssen Research & Development, LLC | $2,145 | Research payment | Cash or cash equivalent | A Phase 3b Multi Center Open label PCI32765 Ibrutinib Long term Extension Study | 2021 | |
| 2021-10-11 | Medical Device Business Services, Inc. | $1,088 | Research payment | Cash or cash equivalent | Safety and Effectiveness Evaluation of the Multi Electrode Radiofrequency Balloon Catheter for the Treatment of Symptoma | 2021 | |
| 2021-09-30 | Janssen Research & Development, LLC | $29,834 | Research payment | Cash or cash equivalent | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2021 | |
| 2021-09-17 | Medical Device Business Services, Inc. | $6,127 | Research payment | Cash or cash equivalent | Safety and Effectiveness Evaluation of the Multi Electrode Radiofrequency Balloon Catheter for the Treatment of Symptoma | 2021 | |
| 2021-09-13 | Medical Device Business Services, Inc. | $59 | Research payment | Cash or cash equivalent | Safety and Effectiveness Evaluation of the Multi Electrode Radiofrequency Balloon Catheter for the Treatment of Symptoma | 2021 | |
| 2021-08-12 | Medical Device Business Services, Inc. | $613 | Research payment | Cash or cash equivalent | Safety and Effectiveness Evaluation of the Multi Electrode Radiofrequency Balloon Catheter for the Treatment of Symptoma | 2021 | |
| 2021-08-09 | Janssen Research & Development, LLC | $6,900 | Research payment | Cash or cash equivalent | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly D | 2021 | |
| 2021-07-19 | Medical Device Business Services, Inc. | $199 | Research payment | Cash or cash equivalent | Safety and Effectiveness Evaluation of the Multi Electrode Radiofrequency Balloon Catheter for the Treatment of Symptoma | 2021 | |
| 2021-07-16 | Janssen Research & Development, LLC | $12,585 | Research payment | Cash or cash equivalent | A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression | 2021 | |
| 2021-06-28 | Medical Device Business Services, Inc. | $19 | Research payment | Cash or cash equivalent | Safety and Effectiveness Evaluation of the Multi Electrode Radiofrequency Balloon Catheter for the Treatment of Symptoma | 2021 | |
| 2021-05-27 | Medical Device Business Services, Inc. | $533 | Research payment | Cash or cash equivalent | Safety and Effectiveness Evaluation of the Multi Electrode Radiofrequency Balloon Catheter for the Treatment of Symptoma | 2021 | |
| 2021-04-23 | Janssen Research & Development, LLC | $1,450 | Research payment | Cash or cash equivalent | A Phase 3b Multi Center Open label PCI32765 Ibrutinib Long term Extension Study | 2021 | |
| 2021-04-12 | Medical Device Business Services, Inc. | $259 | Research payment | Cash or cash equivalent | Safety and Effectiveness Evaluation of the Multi Electrode Radiofrequency Balloon Catheter for the Treatment of Symptoma | 2021 | |
| 2021-04-12 | Medical Device Business Services, Inc. | $199 | Research payment | Cash or cash equivalent | Safety and Effectiveness Evaluation of the Multi Electrode Radiofrequency Balloon Catheter for the Treatment of Symptoma | 2021 | |
| 2021-04-09 | Medical Device Business Services, Inc. | $2,846 | Research payment | Cash or cash equivalent | Safety and Effectiveness Evaluation of the Multi Electrode Radiofrequency Balloon Catheter for the Treatment of Symptoma | 2021 | |
| 2021-04-02 | Janssen Research & Development, LLC | $4,290 | Research payment | Cash or cash equivalent | A Phase 3b Multi Center Open label PCI32765 Ibrutinib Long term Extension Study | 2021 | |
| 2021-03-15 | Medical Device Business Services, Inc. | $1,351 | Research payment | Cash or cash equivalent | Safety and Effectiveness Evaluation of the Multi Electrode Radiofrequency Balloon Catheter for the Treatment of Symptoma | 2021 | |
| 2021-03-01 | Medical Device Business Services, Inc. | $246 | Research payment | Cash or cash equivalent | Safety and Effectiveness Evaluation of the Multi Electrode Radiofrequency Balloon Catheter for the Treatment of Symptoma | 2021 | |
| 2021-02-08 | Medical Device Business Services, Inc. | $1,200 | Research payment | Cash or cash equivalent | Safety and Effectiveness Evaluation of the Multi Electrode Radiofrequency Balloon Catheter for the Treatment of Symptoma | 2021 | |
| 2021-01-28 | Medical Device Business Services, Inc. | $1,166 | Research payment | Cash or cash equivalent | Safety and Effectiveness Evaluation of the Multi Electrode Radiofrequency Balloon Catheter for the Treatment of Symptoma | 2021 | |
| 2020-12-21 | Janssen Research & Development, LLC | $1,430 | Research payment | Cash or cash equivalent | A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study | 2020 | |
| 2020-12-18 | Medical Device Business Services, Inc. | $2,274 | Research payment | Cash or cash equivalent | Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptoma | 2020 | |
| 2020-12-14 | Janssen Research & Development, LLC | $715 | Research payment | Cash or cash equivalent | A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study | 2020 | |
| 2020-12-11 | Medical Device Business Services, Inc. | $1,500 | Research payment | Cash or cash equivalent | Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptoma | 2020 | |
| 2020-11-20 | Janssen Research & Development, LLC | $850 | Research payment | Cash or cash equivalent | A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with | 2020 | |
| 2020-11-06 | Medical Device Business Services, Inc. | $199 | Research payment | Cash or cash equivalent | Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptoma | 2020 | |
| 2020-11-02 | Medical Device Business Services, Inc. | $2,499 | Research payment | Cash or cash equivalent | Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptoma | 2020 | |
| 2020-10-19 | Medical Device Business Services, Inc. | $1,088 | Research payment | Cash or cash equivalent | Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptoma | 2020 | |
| 2020-10-15 | Medical Device Business Services, Inc. | $319 | Research payment | Cash or cash equivalent | Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptoma | 2020 | |
| 2020-10-12 | Janssen Research & Development, LLC | $2,145 | Research payment | Cash or cash equivalent | A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study | 2020 | |
| 2020-10-05 | Janssen Research & Development, LLC | $4,329 | Research payment | Cash or cash equivalent | A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study | 2020 | |
| 2020-08-31 | Medical Device Business Services, Inc. | $2,252 | Research payment | Cash or cash equivalent | Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptoma | 2020 | |
| 2020-07-31 | Medical Device Business Services, Inc. | $808 | Research payment | Cash or cash equivalent | Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptoma | 2020 | |
| 2020-06-29 | Janssen Research & Development, LLC | $2,145 | Research payment | Cash or cash equivalent | A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study | 2020 | |
| 2020-06-08 | Janssen Research & Development, LLC | $1,800 | Research payment | Cash or cash equivalent | A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with | 2020 | |
| 2020-05-11 | Medical Device Business Services, Inc. | $1,500 | Research payment | Cash or cash equivalent | Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptoma | 2020 | |
| 2020-04-17 | Janssen Research & Development, LLC | $17,627 | Research payment | Cash or cash equivalent | A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with | 2020 | |
| 2020-04-16 | Janssen Research & Development, LLC | $250 | Research payment | Cash or cash equivalent | A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study | 2020 | |
| 2020-03-23 | Janssen Research & Development, LLC | $1,430 | Research payment | Cash or cash equivalent | A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study | 2020 | |
| 2020-02-10 | Medical Device Business Services, Inc. | $11,000 | Research payment | Cash or cash equivalent | Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptoma | 2020 | |
| 2019-12-30 | Janssen Research & Development, LLC | $1,430 | Research payment | Cash or cash equivalent | A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study | 2019 | |
| 2019-12-05 | Janssen Research & Development, LLC | $715 | Research payment | Cash or cash equivalent | A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study | 2019 | |
| 2019-09-16 | Janssen Research & Development, LLC | $9,838 | Research payment | Cash or cash equivalent | A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study | 2019 | |
| 2019-09-16 | Janssen Research & Development, LLC | $4,329 | Research payment | Cash or cash equivalent | A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study | 2019 | |
| 2019-03-15 | Janssen Research & Development, LLC | $649 | Research payment | Cash or cash equivalent | A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Kansas City, KS, county Wyandotte County, KS, state Kansas; placed by its city name.
| Measure | Place (city or town) Kansas City, KS | County Wyandotte County, KS | State Kansas |
|---|---|---|---|
| Population B01003 | 155,135 | 167,654 | 2,947,197 |
| Population, 2020 census P1 | 156,607 | 169,245 | 2,937,880 |
| Median age B01002 | 33.9 | 34.3 | 37.4 |
| Under 18 B01001 | 27.6% | 27.4% | 23.8% |
| 65 and over B01001 | 13.2% | 13.3% | 17.0% |
| Households B11001 | 57,016 | 61,562 | 1,174,060 |
| Foreign born B05002 | 18.8% | 17.9% | 7.4% |
| Median household income B19013 | $62,401 | $63,631 | $74,275 |
| Median family income B19113 | $74,728 | $76,514 | $95,810 |
| Per capita income B19301 | $29,317 | $29,843 | $40,978 |
| Poverty rate B17001 | 16.0% | 15.8% | 11.3% |
| Unemployment rate B23025 | 5.8% | 5.7% | 3.9% |
| Civilian labor force B23025 | 77,495 | 84,027 | 1,519,375 |
| Mean commute (minutes) B08013 | 22.4 | 22.3 | 19.7 |
| Bachelor's degree or higher B15003 | 20.8% | 21.2% | 35.6% |
| Housing units B25001 | 64,000 | 68,803 | 1,293,635 |
| Owner-occupied B25003 | 60.9% | 62.0% | 67.2% |
| Renters B25003 | 39.1% | 38.0% | 32.8% |
| Median home value B25077 | $167,400 | $172,300 | $217,200 |
| Median gross rent B25064 | $1,123 | $1,122 | $1,060 |
| White, not Hispanic B03002 | 33.7% | 36.4% | 72.7% |
| Black B03002 | 19.2% | 18.1% | 5.2% |
| Hispanic or Latino B03002 | 35.7% | 34.1% | 13.6% |
| Asian B03002 | 5.3% | 5.2% | 2.9% |
| American Indian and Alaska Native B03002 | 0.3% | 0.3% | 0.4% |
Economy now FRED unemployment 3.8% in Sep 2026 (3.8% a year earlier); per capita personal income $69,149 in 2025, up 25% in five years (+0.7% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Kansas City, KS.
Comments